InflaRx announced that Othmar Zenker, M.D., has been promoted to the newly created position of Chief Medical Officer. Dr. Zenker has served as Head of Clinical Research and Development at InflaRx since 2013. As Chief Medical Officer, he will continue to lead all of the Company's clinical development programs including its novel C5a inhibitors, and he will be crucially involved in the Company's strategic innovative discovery programs. Dr. Zenker has over twenty years of clinical drug development experience at international pharmaceutical companies. Prior to joining InflaRx, he was Global Therapeutic Area Head Immunology at CSL Behring, where he worked from 2000 until 2013. During this time, he was responsible for the clinical development of several products for patients with various rare diseases in the field of immunology, neurology, pulmonology as well as bleeding disorders. Prior to that he worked in clinical development at Wyeth Pharmaceuticals. Dr. Zenker received his M.D. from the Kiel Medical School in Germany.